Private equity deals in pharmaceutical in Canada remained flat in Q3 2024
In the Canadian pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of…
LGP4
-
-
Q3 2024 update: artificial intelligence related private equity activity in the pharmaceutical industry
Analysis of the key themes driving private equity deal activity reveals that artificial intelligence accounted for three pharmaceutical deals announced…
-
Q3 2024 update: ecommerce related M&A activity in the pharmaceutical industry
Analysis of the key themes driving M&A activity reveals that ecommerce accounted for eight pharmaceutical deals announced in Q3 2024,…
-
Q3 2024 update: COVID-19 related private equity activity in the pharmaceutical industry
Analysis of the key themes driving private equity deal activity reveals that COVID-19 accounted for two pharmaceutical deals announced in…
-
Q2 2024 update: electronic medical record (emr) systems related private equity activity in the pharmaceutical industry
Analysis of the key themes driving private equity deal activity reveals that electronic medical record (emr) systems accounted for 2…
-
Q2 2024 update: M&A activity in pharmaceutical in Sweden
In the Swedish pharmaceutical industry, there were 9 M&A deals announced in Q2 2024, worth a total value of $1bn,…
-
Q1 2024 update: personalization related M&A activity in the pharmaceutical industry
Analysis of the key themes driving M&A activity reveals that personalization accounted for 2 pharmaceutical deals announced in Q1 2024,…
-
How future of work private equity performed in the pharmaceutical industry in Q1 2024
Analysis of the key themes driving private equity deal activity reveals that future of work accounted for 3 pharmaceutical deals…
-
Q1 2024 update: individualism & expression related M&A activity in the pharmaceutical industry
Analysis of the key themes driving M&A activity reveals that individualism & expression accounted for 2 pharmaceutical deals announced in…
-
How immuno-oncology M&A performed in the pharmaceutical industry in Q3 2024
Analysis of the key themes driving M&A activity reveals that immuno-oncology accounted for 18 pharmaceutical deals announced in Q3 2024,…